101,834 Shares in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Purchased by TIAA Trust National Association

TIAA Trust National Association acquired a new stake in shares of Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 101,834 shares of the company’s stock, valued at approximately $207,000.

Separately, Atlas Legacy Advisors LLC bought a new stake in shares of Lixte Biotechnology in the fourth quarter valued at approximately $26,000. 5.10% of the stock is owned by hedge funds and other institutional investors.

Lixte Biotechnology Trading Up 1.6 %

LIXT opened at $1.27 on Friday. Lixte Biotechnology Holdings, Inc. has a 12 month low of $1.02 and a 12 month high of $3.87. The company has a market cap of $2.86 million, a PE ratio of -0.73 and a beta of 0.19. The company has a 50 day moving average of $1.70 and a 200 day moving average of $1.86.

Lixte Biotechnology (NASDAQ:LIXT) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.27) EPS for the quarter.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.